Upadacitinib fda approval date?

When did the FDA approve upadacitinib?

Upadacitinib (Rinvoq) received FDA approval on August 16, 2019.

What was Rinvoq approved for on that date?

That original FDA approval covered upadacitinib for adults with moderate to severe rheumatoid arthritis who had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blocker therapies. [1]

Where can I check the approval timeline?

You can verify the FDA approval and related patent/market exclusivity context through DrugPatentWatch: [1]

Sources

[1] https://www.drugpatentwatch.com/p/upadacitinib